🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Eloxx Pharmaceuticals, Inc. (ELOX)
NASDAQ: ELOX · Real-Time Price · USD
10.65
+0.24 (2.31%)
At close: Nov 19, 2026, 4:00 PM EST
10.66
+0.01 (0.09%)
After-hours: Nov 19, 2026, 4:10 PM EST

Eloxx Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Eloxx Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $37.5. The average 1-year stock price forecast is 252.11% higher than the current stock price, while the lowest is $32 (+200.47%) and the highest is $40 (+275.59%).

Price Target: $37.5 (+252.11%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$32$37.5$39$40
Change+200.47%+252.11%+266.20%+275.59%

Analyst Ratings

The average analyst rating for Eloxx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingFeb '24Jul '26Aug '26Sep '26Oct '26
Strong Buy12345
Buy00000
Hold00000
Sell00000
Strong Sell00000
Total12345

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Leerink Partners
Leerink Partners
Buy
Reiterates
$32
BuyReiterates$32+200.47%Nov 17, 2026
Guggenheim
Guggenheim
Buy
Reiterates
$43 → $40
BuyReiterates$43 → $40+275.59%Oct 28, 2026
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Initiates
n/a
BuyInitiatesn/an/aOct 15, 2026
Lucid Capital
Lucid Capital
Buy
Initiates
$38
BuyInitiates$38+256.81%Aug 20, 2026
LifeSci Capital
LifeSci Capital
Buy
Maintains
$40
BuyMaintains$40+275.59%Aug 12, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.43
EPS Next Year
-3.58
from -2.43
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
---6.36M--
Gross Profit
---6.36M--
Gross Margin
---100.00%-90.00%
Operating Income
-42.35M-34.42M-17.29M-2.47M-6.44M-21.20M
Net Income
-66.73M-36.07M-17.05M-3.14M-6.00M-19.95M
EPS
------2.43
Free Cash Flow
------4.60M
No. Analysts
-----4
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-2.43
Avg-2.43
Low-2.43

EPS Growth

EPS Growth20272028
High-
Avg-
Low-